In 2023, Iceland led European countries in antibacterial medicine sales at USD 22 PPP per capita, despite a slight year-on-year decline of 1.23%. The Czech Republic follows at USD 18.6 PPP per capita, experiencing a modest 0.44% increase, while Spain posted a stronger growth of 1.32%, reaching USD 17.3 PPP per capita. Norway, Sweden, and Finland exhibit lower sales, with Norway at USD 8.4 PPP per capita (+0.73%), and Sweden alongside Finland both at USD 8.2 PPP per capita (Finland seeing a significant 4.82% decline). Austria stands at the bottom with USD 7.8 PPP per capita, down 1.93%. Over five years, the CAGR provides a comprehensive view of average annual change.
Future trends to watch include:
- Potential recovery or further declines in Finland and Austria.
- Continued growth in Spain and the Czech Republic.
- Monitoring the impact of new health policies and economic conditions across Europe.
- Analyzing the influence of demographic changes and evolving healthcare demands on antibacterial usage.
Top countries in Antibacterial Medicine Sales by Country
| # | 7 Countries | US Dollars PPP Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Iceland | 22 | 2023 | 0% | -1.23% | View data |
| 2 | 2 Czech Republic | 18.6 | 2023 | +3.91% | +0.44% | View data |
| 3 | 3 Spain | 17.3 | 2023 | +0.58% | +1.32% | View data |
| 4 | 4 Norway | 8.4 | 2023 | -1.18% | +0.73% | View data |
| 5 | 5 Sweden | 8.2 | 2023 | +2.5% | +1.27% | View data |
| 6 | 6 Finland | 8.2 | 2023 | -1.2% | -4.82% | View data |
| 7 | 7 Austria | 7.8 | 2023 | 0% | -1.93% | View data |
